Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA
- Conditions
- Venous Thromboembolism
- First Posted Date
- 2010-06-08
- Last Posted Date
- 2014-01-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1676
- Registration Number
- NCT01139658
- Locations
- ๐ซ๐ท
Boehringer Ingelheim Investigational Site 19, Lyon, France
๐ซ๐ทBoehringer Ingelheim Investigational Site 30, Angers, France
๐ซ๐ทBoehringer Ingelheim Investigational Site 40, Beauvais, France
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT01136174
- Locations
- ๐ฏ๐ต
1199.31.002 Boehringer Ingelheim Investigational Site, Bunkyo-ku,Tokyo, Japan
๐ฏ๐ต1199.31.004 Boehringer Ingelheim Investigational Site, Hamamatsu, Shizuoka, Japan
๐ฏ๐ต1199.31.006 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan
A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 174
- Registration Number
- NCT01136408
- Locations
- ๐ฏ๐ต
1160.49.014 Boehringer Ingelheim Investigational Site, Suita, Osaka, Japan
๐ฏ๐ต1160.49.027 Boehringer Ingelheim Investigational Site, Iizuka,Fukuoka, Japan
๐ฏ๐ต1160.49.013 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto, Japan
TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch
- Conditions
- Hypertension
- Interventions
- Drug: telmisartan/amlodipine
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 502
- Registration Number
- NCT01134393
- Locations
- ๐ฎ๐น
1235.33.39009 Boehringer Ingelheim Investigational Site, Arezzo, Italy
๐ฎ๐น1235.33.39002 Boehringer Ingelheim Investigational Site, Bologna, Italy
๐ฉ๐ช1235.33.49010 Boehringer Ingelheim Investigational Site, Berlin, Germany
Non-interventional Observational Study With Viramuneยฎ in HIV to Evaluate Gender Specific Data
- Conditions
- HIV Infections
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 265
- Registration Number
- NCT01134939
- Locations
- ๐ฉ๐ช
Boehringer Ingelheim Investigational Site 21, Leipzig, Germany
๐ฉ๐ชBoehringer Ingelheim Investigational Site 10, Berlin, Germany
๐ฉ๐ชBoehringer Ingelheim Investigational Site 11, Berlin, Germany
to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT01134965
- Locations
- ๐ฉ๐ช
511.158.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 488
- Registration Number
- NCT01132313
- Locations
- ๐บ๐ธ
1241.21.0004 Boehringer Ingelheim Investigational Site, San Francisco, California, United States
๐บ๐ธ1241.21.0012 Boehringer Ingelheim Investigational Site, Arlington, Texas, United States
๐บ๐ธ1241.21.0003 Boehringer Ingelheim Investigational Site, La Jolla, California, United States
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo BI 10773 high doseDrug: BI 10773 high doseDrug: BI 10773 low doseDrug: Placebo BI 10773 low dose
- First Posted Date
- 2010-05-27
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7064
- Registration Number
- NCT01131676
- Locations
- ๐บ๐ธ
1245.25.10077 Boehringer Ingelheim Investigational Site, Yardley, Pennsylvania, United States
๐บ๐ธ1245.25.10056 Boehringer Ingelheim Investigational Site, Gilbert, Arizona, United States
๐บ๐ธ1245.25.10200 Boehringer Ingelheim Investigational Site, Delray Beach, Florida, United States
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 17183
- Registration Number
- NCT01126437
- Locations
- ๐บ๐ธ
205.452.01345 Boehringer Ingelheim Investigational Site, Lancaster, California, United States
๐บ๐ธ205.452.01362 Boehringer Ingelheim Investigational Site, Tustin, California, United States
๐บ๐ธ205.452.01133 Boehringer Ingelheim Investigational Site, St. Petersburg, Florida, United States
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 508
- Registration Number
- NCT01125566
- Locations
- ๐ฆ๐น
Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz, Austria
๐ฆ๐ทSanatorio Parque, Rosario, Argentina
๐บ๐ธIronwood Cancer and Research Centers, Chandler, Arizona, United States